Shopping Cart
Remove All
Your shopping cart is currently empty
Glembatumumab
😃Good
Catalog No. T77439Cas No. 1020264-78-1
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
Glembatumumab
Glembatumumab
😃Good
Catalog No. T77439Cas No. 1020264-78-1
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | In Stock | In Stock | |
| 5 mg | $588 | In Stock | In Stock | |
| 10 mg | $947 | - | In Stock | |
| 25 mg | $1,380 | - | In Stock | |
| 50 mg | $1,890 | - | In Stock | |
| 100 mg | $2,550 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.31% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin). |
| In vitro | Glembatumumab vedotin (CR011-vcMMAE) exhibits minimal growth inhibition at a concentration of 0.16 μg/mL in UACC62 melanoma cells without prior MEK inhibitor pretreatment for 72 hours. In contrast, the same dose of CR011-vcMMAE shows stronger growth inhibition in UACC62 cells pre-treated with a MEK inhibitor[1]. |
| In vivo | Glembatumumab vedotin, administered via intravenous injection at a dose of 2.5 mg/kg three times within 7 days, inhibits tumor growth and demonstrates good tolerance in CB17SC scid?/? female xenograft mice[2]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GPNMB |
| Molecular Weight | 145.56 kDa |
| Cas No. | 1020264-78-1 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Glembatumumab | purchase Glembatumumab | Glembatumumab cost | order Glembatumumab | Glembatumumab in vivo | Glembatumumab in vitro | Glembatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.